Pricing Log in Create free account
Friday 6 November 2026 Export BIO.B’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

BIO.B Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.9%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

379.50 15.35 +4.22%
Market cap
$10.3B
P/E
9.9×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
3.24
Beneish M
−2.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Bio-Rad Laboratories, Inc. (BIO.B) Price to free cash flow

Alert me on Price to free cash flow

As of 27 October 2026, Bio-Rad Laboratories, Inc. (BIO.B) trades at a price to free cash flow of 30.7×. Over the past ten years it has ranged from 0.0× (March 2018) to 555× (June 2017); the current reading is higher than 25% of that period. That is above the Medical Devices industry median of 28.8× and above the Healthcare sector median of 21.1×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 22.5× (28.60%)
FY2024 31.5× (25.89%)
FY2023 42.5× (70.45%)
FY2022 144× 259.55%
FY2021 40.0× 12.30%
FY2020 35.6× 18.92%
FY2019 29.9× (30.18%)
FY2018 42.9× —
FY2017 0.0× —
FY2016 72.1× 30.74%

Quarterly newest first

Period Price to free cash flow Change
Sep 2026 29.6× 32.43%
Jun 2026 22.3× 7.00%
Mar 2026 20.9× (7.18%)
Dec 2025 22.5× (0.64%)
43 more quarters

Against its own ten years

Low 0.0× High 555×
Ten-year median 39.9×
Current reading's percentile 25

Price to free cash flow against peers

Company Price to free cash flow
SNN Smith & Nephew SNATS, Inc. compare 7.1×
GMED Globus Medical, Inc. compare 14.5×
BIO Bio-Rad Laboratories, Inc. compare 30.0×
BIO.B Bio-Rad Laboratories, Inc. 30.7×
BRKR Bruker Corporation compare 32.9×
PODD Insulet Corporation compare 46.4×
PEN Penumbra, Inc. compare 63.1×
TXG 10x Genomics compare 63.3×
GKOS Glaukos Corporation compare 360×
Medical Devices industry median 28.8×
Healthcare sector median 21.1×
Market median 14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on BIO.B